


PRODUCT INFORMATION



GW 803430
Item No. 13948

CAS Registry No.: 515141-51-2
Formal Name: 6-(4-chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-thieno[3,2-d]pyrimidin-4(3H)-one
Synonym: GW 3430
MF: C₂₅H₂₄ClN₃O₃S
FW: 482.0
Purity: ≥98%
UV/Vis.: λ_{max}: 228, 264, 312 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GW 803430 is supplied as a crystalline solid. A stock solution may be made by dissolving the GW 803430 in the solvent of choice. GW 803430 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of GW 803430 in these solvents is approximately 2 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of GW 803430 can be prepared by directly dissolving the crystalline solid in aqueous buffers. GW 803430 is slightly soluble in PBS, pH 7.2. We do not recommend storing the aqueous solution for more than one day.

Description

GW 803430 is an antagonist of melanin-concentrating hormone receptor 1 (MCH₁; IC₅₀ = 0.5 nM).¹ It reduces cumulative body weight and food intake in diet-induced obese rats when administered at doses of 1 and 3 mg/kg.² GW 803430 (10 and 30 mg/kg) decreases marble-burying behavior in mice, indicating anxiolytic activity, but does not affect performance in the rotarod test. It also reduces immobility time in the forced swim and tail suspension tests in mice at doses of 3 and 10 mg/kg, respectively, indicating antidepressant-like activity.

References

1. Hertzlog, D.L., Al-Barabzanji, K.A., Bigham, E.C., *et al.* The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. *Bioorg. Med. Chem. Lett.* **16(18)**, 4723-4727 (2006).
2. Gehlert, D.R., Rasmussen, K., Shaw, J., *et al.* Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. *J. Pharmacol. Exp. Ther.* **329(2)**, 429-438 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM